Evidence map›Paper›PMID 35972640›Full record

ArticleHepatology international2022

Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study.

Ke Su, Yanlin Liu, Pan Wang, Kun He, Fei Wang, Hao Chi, Mingyue Rao, Xueting Li, Lianbin Wen, Yanqiong Song and 30 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  18. Tumour necrosis factor-Frontiers in nutrition · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 4 institutions in 1 country.

Ke Su *Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Yanlin Liu *Department of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Pan Wang *Clinical Skills Center, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Kun HeClinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Fei WangDepartment of General Surgery, Luxian People's Hospital, Luzhou, 646199, China.
Hao ChiClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Mingyue RaoDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Xueting LiDepartment of Oncology, 363 Hospital, Chengdu, 610041, China.
Lianbin WenDepartment of Geriatric Cardiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, 610072, China.
Yanqiong SongDepartment of Radiotherapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610042, China.
Jianwen ZhangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Tao GuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Ke XuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Qi LiDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Jiali ChenDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Zhenying WuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Han LiDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China.
Weihong HuangClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Lan ChenDepartment of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China.
Jian TongDepartment of Spinal Surgery, No.1 Orthopedics Hospital of Chengdu, Chengdu, 610000, China.
Hongyan LiDepartment of Anesthesiology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China.
Xunjie FengClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Siyu ChenClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Binbin YangClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Hongping JinClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Yue YangClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Hanlin LiuClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Chao YangClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Ming WuClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Fangyu XiongDepartment of Medical Inspection Technology, Southwest Medical University, Luzhou, 646000, China.
Keyi PengClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Lechuan ZhuClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Yaoyang XuClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Xue TangClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Zunyuan TanClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Xiaotong LuoClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Hanyue ZhengClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Yuxin ZhangClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Lu GuoDepartment of Ophthalmology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 646000, Sichuan, China. guolu68@163.com.
Yunwei HanDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, 46000, Sichuan, China. Lanpaoxiansheng@126.com.ORCID http://orcid.org/0000-0002-0942-9095
Southwest Medical University · CNAffiliated Hospital of Southwest Medical University · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the diagnostic value of plasma heat-shock protein 90α (HSP90α) in hepatocellular carcinoma (HCC) has been previously reported, the causal effect of the plasma HSP90α levels on HCC prognosis remains largely unclear. To this extent, we sought to assess whether the plasma HSP90α acts as a prognostic factor for HCC patients.

methodsA total of 2150 HCC patients were included in this retrospective study between August 2016 and July 2021. Plasma HSP90α levels were tested within a week before treatment and their association with prognosis was assessed.

resultsAn optimal cutoff value of 143.5 for the HSP90α based on the overall survival (OS) was determined using the X-tile software. HCC patients with HSP90α < 143.5 ng/mL (low HSP90α) before and after propensity score matching (PSM) indicated longer median OS (mOS) relative to those with HSP90α ≥ 143.5 ng/mL (high HSP90α) (37.0 vs. 9.0 months, p < 0.001; 19.2 vs. 9.6 months, p < 0.001; respectively). In addition, the high HSP90α plasma level is an independent poor prognostic factor for OS in HCC patients. In our subgroup analysis, including the supportive care group, surgery group, transarterial chemoembolization (TACE) group, adjuvant TACE group, an immune checkpoint inhibitor (ICI) plus targeted therapy group, and TACE plus ICI group, the high HSP90α group demonstrated better OS compared to the low HSP90α group. Moreover, in the supportive care, TACE, ICI plus targeted therapy, TACE plus ICI groups, and high HSP90α levels were also an independent poor prognostic factors for OS.

conclusionsOur study confirmed that the plasma HSP90α level can be used as a prognostic biomarker for HCC.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsBiomarkersHeat-Shock ProteinsHSP90 Heat-Shock ProteinsHumansImmune Checkpoint InhibitorsPrognosisRetrospective StudiesBiomarkersHeat-Shock ProteinsHSP90AA2P protein, humanHSP90 Heat-Shock ProteinsImmune Checkpoint InhibitorsBiomarkerHeat-shock protein 90αHepatocellular carcinomaImmune checkpoint inhibitorOverall survivalPredictive biomarkerPrimary liver cancerPrognostic factorTargeted therapyTransarterial chemoembolization

Identifiers

PMID35972640
PMCPMC9525341
OpenAlexW4291972596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.